Urology · Bay Shore, NY
NPI
1114950383
Since 2006
Specialty
Urology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
332 E Main St, .
Bay Shore, NY, 11706
Phone (631) 665-3737
Groups this clinician bills Medicare through
Medicare paid, 2024
$306K
30,483 services
Medicare patients, 2024
867
Average age 75
Drug cost, 2024
$288K
3,336 prescriptions
Company payments, 2025
$56.69
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edward A Loizides was code 81003 (clinical chemistry), 1,454 times for 758 patients. In total Edward A Loizides billed 30,483 services in 39 codes, and Medicare paid $306K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 81003 Clinical Chemistry | Office | 1,454 | 758 | $2.19 | $3,179 |
| 99214 Office E&M - Established | Office | 1,349 | 722 | $108.83 | $147K |
| 99212 Office E&M - Established | Office | 316 | 184 | $52.30 | $17K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 220 | 26 | $138.30 | $30K |
| 99204 Office E&M - New | Office | 169 | 169 | $141.38 | $24K |
| 52000 Cystourethroscopy | Office | 78 | 72 | $223.40 | $17K |
| 96372 Injection Administration | Office | 75 | 15 | $13.34 | $1,000 |
| 52281 Calculus Removal - Urinary | Office | 70 | 67 | $291.93 | $20K |
| 96402 Chemotherapy Administration | Office | 58 | 27 | $34.05 | $1,975 |
| 99213 Office E&M - Established | Office | 38 | 35 | $72.59 | $2,759 |
| 51700 Other Organ Systems | Office | 38 | 17 | $41.92 | $1,593 |
| 51710 Other Organ Systems | Office | 34 | 14 | $122.63 | $4,169 |
| 53265 Other Organ Systems | Office | 33 | 28 | $149.67 | $4,939 |
| 99215 Office E&M - Established | Office | 21 | 17 | $165.29 | $3,471 |
| J1580 Injection, garamycin, gentamicin, up to 80 mg | Office | 16 | 14 | $1.98 | $31.69 |
By year: 2022 $353K for 14,665 services; 2023 $343K for 26,597 services; 2024 $306K for 30,483 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,454 | 758 | $2.19 | $3,179 |
Medicare prescription drug claims, 2024
In 2024, the drug Edward A Loizides prescribed most often to Medicare patients was Tamsulosin Hcl, with 808 prescriptions and refills. In total Edward A Loizides wrote 3,336 Medicare prescriptions that cost $288K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 808 | 2,148 | 266 | $12K |
| Finasteride Generic | 495 | 1,407 | 153 | $6,977 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 471 | 494 | 231 | $5,379 |
| Cefpodoxime Proxetil Generic | 276 | 283 | 164 | $12K |
| Ciprofloxacin Hcl Generic | 127 | 127 | 74 | $480 |
| Gemtesa Vibegron | 99 | 131 | 19 | $61K |
| Cefadroxil Generic | 75 | 82 | 39 | $415 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 70 | 178 | 20 | $1,010 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 57 | 68 | 32 | $370 |
| Dutasteride Generic | 54 | 158 | 16 | $2,180 |
| Sildenafil Citrate Generic | 50 | 62 | 14 | $220 |
| Bicalutamide Generic | 47 | 123 | 16 | $1,870 |
| Potassium Citrate Er Potassium Citrate | 42 | 90 | Under 11 | $4,424 |
| Estradiol Generic | 41 | 94 | 22 | $3,680 |
| Cephalexin Generic | 40 | 59 | Under 11 | $171 |
Brand drugs: 278 claims; generic drugs: 3,058 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Edward A Loizides $56.69 ($56.69 in general payments such as food, travel and fees) from 1 company. The largest payer was Urogen Pharma, Inc. with $56.69.
| Company | Payments | Amount |
|---|---|---|
| Urogen Pharma, Inc. URGN | 2 | $56.69 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.